Skip to main content
Banu (Karimi) Karimi-Shah, MD, Pulmonology, Falls Church, VA, Inova Alexandria Hospital

BanuAbbas(Karimi)Karimi-ShahMD

Pulmonology • Falls Church, VA

Critical Care Medicine, Pleural Disease

Physician

Join to view full profile

Are you Dr. Karimi-Shah?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 73 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. Banu (Karimi) Karimi-Shah, MD is a pulmonologist in Falls Church, Virginia. She is currently licensed to practice medicine in Virginia, Maryland, and Massachusetts. She is affiliated with Inova Alexandria Hospital, Inova Mount Vernon Hospital, and Inova Loudoun Hospital.

Education & Training

  • Massachusetts General Hospital/BIDMC/Harvard Medical School
    Massachusetts General Hospital/BIDMC/Harvard Medical SchoolFellowship, Pulmonary Disease and Critical Care Medicine, 2003 - 2006
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 2000 - 2003
  • Boston University School of Medicine
    Boston University School of MedicineClass of 2000

Certifications & Licensure

  • VA State Medical License
    VA State Medical License 2009 - 2024
  • MD State Medical License
    MD State Medical License 2008 - 2010
  • MA State Medical License
    MA State Medical License 2002 - 2009
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Critical Care Medicine
  • American Board of Internal Medicine Pulmonary Disease

Publications & Presentations

PubMed

Press Mentions

  • FDA Advisors Tepid on Drug Candidate for COVID Inpatients
    FDA Advisors Tepid on Drug Candidate for COVID InpatientsNovember 10th, 2022
  • FDA Approves Symdeko for Treatment of CF Children, Ages 6 to 11, with Certain CFTR Mutations
    FDA Approves Symdeko for Treatment of CF Children, Ages 6 to 11, with Certain CFTR MutationsJune 25th, 2019
  • FDA Expands Approval of CF Treatment to Include Patients Ages 6 and Older
    FDA Expands Approval of CF Treatment to Include Patients Ages 6 and OlderJune 24th, 2019
  • Join now to see all

Hospital Affiliations

Dr. Banu Karimi-Shah, Dr. Banu Karimi-Shah, MD, Dr. B Karimi-Shah, Dr. Banu Abbas Karimi-Shah